However, in one study DI-AIH was defined as a drug reaction with well-documented cause of DI-AIH, with positive ANA or SMA or elevated IgG, 10 times upper limit of normal ALT, with hepatocellular (HC) or mixed pattern or requirement of corticosteroids in patients with hepatocellular type, defined as no improvement in ALT and AST after discontinuation of the implicated agent (Björnsson et al., 2017). Here, BTG3 is linked to autoimmune hepatitis.